{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:22:31Z","timestamp":1790774551987,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ctrv.2025.102974","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T11:01:15Z","timestamp":1749898875000},"page":"102974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective"],"prefix":"10.1016","volume":"139","author":[{"given":"Saby","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karishma","family":"Shelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen J.","family":"Markus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Kewley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie I.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albig\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.102974_b0005","unstructured":"World Health Organization. \u201cCancer.\u201d https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer (accessed 18th Decemebr 2023."},{"key":"10.1016\/j.ctrv.2025.102974_b0010","unstructured":"The Global Cancer Observatory. \u201cWorld Statistics at a Glance, 2022.\u201d https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf (accessed."},{"key":"10.1016\/j.ctrv.2025.102974_b0015","unstructured":"The American Cacner Society. \u201cIntravenous (IV) Lines, Catheters, and Ports Used in Cancer Treatment.\u201d https:\/\/www.cancer.org\/cancer\/managing-cancer\/making-treatment-decisions\/tubes-lines-ports-catheters.html (accessed."},{"issue":"9","key":"10.1016\/j.ctrv.2025.102974_b0020","article-title":"Programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immunotherapy: a promising breakthrough in cancer therapeutics","volume":"15","author":"Abaza","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ctrv.2025.102974_b0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2017.00064","article-title":"Advancing cancer therapy with present and Emerging immuno-oncology approaches","volume":"7","author":"Kamta","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0030","doi-asserted-by":"crossref","unstructured":"C. M. Jackisch, V. Maintz, C. Hell, S. Ataseven, B., \u201cSubcutaneous administration of monoclonal antibodies in oncology,\u201d (in English), Geburtshilfe und Frauenheilkunde, vol. 74, no. 4, pp. 343-349, April 2014, doi: 10.1055\/s-0034-1368173.","DOI":"10.1055\/s-0034-1368173"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102974_b0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"\u201cSubcutaneous Administration of Biotherapeutics: an overview of current challenges and opportunities,\u201d (in eng)","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102974_b0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0034-1368173","article-title":"\u201cSubcutaneous Administration of Monoclonal Antibodies in oncology,\u201d (in eng)","volume":"74","author":"Jackisch","year":"2014","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102974_b0045","first-page":"334","article-title":"\u201cSubcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use,\u201d (in eng), journal of B.U.ON. : official journal of the Balkan union of","volume":"22","author":"Lazaro Cebas","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2025.102974_b0050","doi-asserted-by":"crossref","unstructured":"M. J. Page et al., \u201cThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews,\u201d (in eng), Bmj, vol. 372, p. n71, Mar 29 2021, doi: 10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"10.1016\/j.ctrv.2025.102974_b0055","series-title":"for Reviews and dissemination","article-title":"\u201cSystematic reviews: CRD's guidance for undertaking reviews in health care,\u201d no","author":"Akers","year":"2009"},{"key":"10.1016\/j.ctrv.2025.102974_b0060","doi-asserted-by":"crossref","unstructured":"C. H. Jackisch, R. Stroyakovskiy, D. Ahn, J. S. Melichar, B. Chen, S. C. Kim, S. B. Lichinitser, M. Staroslawska, E. Kunz, G. Falcon, S. Chen, S. T. Crepelle-Flechais, A. Heinzmann, D. Shing, M. Pivot, X., \u201cHannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up,\u201d (in English), European Journal of Cancer, vol. 62, pp. 62-75, 01 Jul 2016, doi: 10.1016\/j.ejca.2016.03.087.","DOI":"10.1016\/j.ejca.2016.03.087"},{"issue":"4 Supplement","key":"10.1016\/j.ctrv.2025.102974_b0065","first-page":"1","article-title":"Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: final analysis from the phase III, open-label, randomized HannaH study","volume":"78","author":"Jackisch","year":"2017","journal-title":"(in English), Cancer Research Conference: San Antonio Breast Cancer Symposium, SABCS, Conference Abstract"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102974_b0070","doi-asserted-by":"crossref","first-page":"e190339","DOI":"10.1001\/jamaoncol.2019.0339","article-title":"Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial","volume":"5","author":"Jackisch","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0075","unstructured":"G. Cartron et al., \u201cRandomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low\u2013Tumor Burden Follicular Lymphoma: Results of a LYSA Study,\u201d Journal of Clinical Oncology, p. JCO. 22.02327, 2023."},{"key":"10.1016\/j.ctrv.2025.102974_b0080","doi-asserted-by":"crossref","unstructured":"G. Cartron et al., \u201cSubcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study,\u201d ed: American Society of Clinical Oncology, 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.7512"},{"key":"10.1016\/j.ctrv.2025.102974_b0085","doi-asserted-by":"crossref","unstructured":"A. M. Davies, F. Mihaljevic, B. Mercadal, S. Siritanaratkul, N. Solal-Celigny, P. Boehnke, A. Berge, C. Genevray, M. Zharkov, A. Dixon, M. Brewster, M. Barrett, M. MacDonald, D., \u201cEfficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial,\u201d (in English), The Lancet Haematology, vol. 4, no. 6, pp. e272-e282, June 2017, doi: 10.1016\/S2352-3026%2817%2930078-9.","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"10.1016\/j.ctrv.2025.102974_b0090","unstructured":"M. J. K. Rummel, T. M. Aversa, F. Brugger, W. Capochiani, E. Plenteda, C. Re, F. Task, P. McIntyre, C. Meier, O. Osborne, S. Smith, R. Grigg, A., \u201cEfficacy and safety of subcutaneous or intravenous administration of rituximab in patients with cd20+ diffuse large b-cell lymphoma or follicular lymphoma: Final results of the randomized, open-label, crossover, prefmab study,\u201d (in English), Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH, Conference Abstract vol. 130, no. Supplement 1, 2017. [Online]. Available: http:\/\/www.bloodjournal.org\/content\/130\/Suppl_1\/2834 http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexa&AN=620334344."},{"key":"10.1016\/j.ctrv.2025.102974_b0095","doi-asserted-by":"crossref","unstructured":"P. A. Lugtenburg, I. Berenschot, H. Ilhan, O. Marolleau, J. P. Nagler, A. Rueda, A. Tani, M. Turgut, M. Osborne, S. Smith, R. Pfreundschuh, M., \u201cEfficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study,\u201d (in English), Haematologica, Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't vol. 102, no. 11, pp. 1913-1922, 11 2017, doi: doi: 10.3324\/haematol.2017.173583.","DOI":"10.3324\/haematol.2017.173583"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102974_b0100","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2025.102974_b0105","doi-asserted-by":"crossref","unstructured":"R. Yao et al., \u201cOnce-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China,\u201d Medicine, vol. 98, no. 39, 2019.","DOI":"10.1097\/MD.0000000000017147"},{"key":"10.1016\/j.ctrv.2025.102974_b0110","doi-asserted-by":"crossref","unstructured":"H.-M. Zhang et al., \u201cAnalysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods,\u201d Cancer Management and Research, pp. 8295-8302, 2019.","DOI":"10.2147\/CMAR.S218979"},{"key":"10.1016\/j.ctrv.2025.102974_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208920","article-title":"\u201cClinical outcomes of bortezomib-based therapy in myeloma,\u201d (in english)","author":"Djebbari","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102974_b0120","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3892\/etm.2016.3738","article-title":"\u201cPeripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma,\u201d (in english)","volume":"12","author":"Liu","year":"2016","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ctrv.2025.102974_b0125","doi-asserted-by":"crossref","unstructured":"Y. D. Xu, S. Mao, X. An, G. Li, Z. Wang, Y. Fulciniti, M. Ho, M. Lin, J. Sui, W. Liu, W. Zou, D. Yi, S. Huang, W. Liu, H. Lv, R. Li, J. Wang, T. Du, C. Munshi, N. C. Qiu, L., \u201cTolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma,\u201d (in English), Clinical Lymphoma, Myeloma and Leukemia, vol. 18, no. 6, pp. 422-430, June 2018, doi: 10.1016\/j.clml.2018.03.006.","DOI":"10.1016\/j.clml.2018.03.006"},{"key":"10.1016\/j.ctrv.2025.102974_b0130","unstructured":"P. P. Moreau, H. Grosicki, S. Karamanesht, E. Leleu, X. Grishunina, M. Rekhtman, G. Masliak, Z. Robak, T. Shubina, A. Arnulf, B. Kropff, M. Cavet, J. Esseltine, D. L. Feng, H. Skee, D. Van De Velde, H. Deraedt, W. Harousseau, J. L., \u201cA phase 3, randomized, international study (MMY-3021) comparing subcutaneous (SC) and intravenous (IV) administration of bortezomib in patients (PTS) with relapsed multiple myeloma (MM),\u201d (in English), Haematologica, Conference Abstract vol. 1), pp. S87-S88, 01 May 2011. [Online]. Available: http:\/\/haematologica.org\/content\/96\/supplement_1\/S1.full-text.pdf+html http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed12&AN=71695021."},{"key":"10.1016\/j.ctrv.2025.102974_b0135","doi-asserted-by":"crossref","unstructured":"P. P. Moreau, H. Grosicki, S. Karamanesht, I. Leleu, X. Grishunina, M. Rekhtman, G. Masliak, Z. Robak, T. Shubina, A. Arnulf, B. Kropff, M. Cavet, J. Esseltine, D. L. Feng, H. Girgis, S. van de Velde, H. Deraedt, W. Harousseau, J. L., \u201cSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study,\u201d (in English), The Lancet Oncology, vol. 12, no. 5, pp. 431-440, May 2011, doi: 10.1016\/S1470-2045%2811%2970081-X.","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"10.1016\/j.ctrv.2025.102974_b0140","doi-asserted-by":"crossref","unstructured":"P. K. Moreau, I. I. Domnikova, N. Kyselyova, M. Y. Vilchevska, K. V. Doronin, V. A. Schmidt, A. Hulin, C. Leleu, X. Esseltine, D. L. Venkatakrishnan, K. Skee, D. Feng, H. Girgis, S. Cakana, A. Van De Velde, H. Deraedt, W. Facon, T., \u201cPharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma,\u201d (in English), Clinical Pharmacokinetics, vol. 51, no. 12, pp. 823-829, December 2012, doi: 10.1007\/s40262-012-0010-0.","DOI":"10.1007\/s40262-012-0010-0"},{"key":"10.1016\/j.ctrv.2025.102974_b0145","doi-asserted-by":"crossref","unstructured":"B. P. Arnulf, H. Grosicki, S. Karamanesht, I. Leleu, X. van de Velde, H. Feng, H. Cakana, A. Deraedt, W. Moreau, P., \u201cUpdated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma,\u201d (in English), Haematologica, vol. 97, no. 12, pp. 1925-1928, 01 Dec 2012, doi: 10.3324\/haematol.2012.067793.","DOI":"10.3324\/haematol.2012.067793"},{"key":"10.1016\/j.ctrv.2025.102974_b0150","unstructured":"S. W. Yan, P. Xu, Y. Zheng, H. Ma, L. Jin, S. Fu, C. Wu, D., \u201cRetrospective study of the efficacy, economy and safety of treatment with subcutaneous injection of bortezomib in de novo patients with multiple myeloma,\u201d (in English), Haematologica, Conference Abstract vol. 101 (Supplement 1), pp. 801-802, June 2016. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4894295\/pdf\/haematol_2016_s1.pdf http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed17&AN=615550154."},{"key":"10.1016\/j.ctrv.2025.102974_b0155","unstructured":"M. S. G. Infante, I. Munoz, C. Heras, C. Foncillas, M. A. Marin, K. Hernandez, J. A., \u201cA single centre real life experience on multiple myeloma (MM) patients: Subcutaneous (SUBQ) versus intravenous (IV) bortezomib (BOR),\u201d (in English), Haematologica, Conference Abstract vol. 101 (Supplement 1), pp. 802-803, June 2016. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4894295\/pdf\/haematol_2016_s1.pdf http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed17&AN=615550262."},{"key":"10.1016\/j.ctrv.2025.102974_b0160","doi-asserted-by":"crossref","unstructured":"M. S. Damlaj, N. H. Oliveira, J. L. Ketterling, R. P. Hashmi, S. Witzig, T. Nowakowski, G. Call, T. G. Shanafelt, T. D. Ding, W. Hogan, W. J. Litzow, M. R. Patnaik, M. M., \u201cImpact of alemtuzumab therapy and route of administration in T-prolymphocytic leukemia: A single-center experience,\u201d (in English), Clinical Lymphoma, Myeloma and Leukemia, vol. 15, no. 11, pp. 699-704, November 2015, doi: 10.1016\/j.clml.2015.07.643.","DOI":"10.1016\/j.clml.2015.07.643"},{"key":"10.1016\/j.ctrv.2025.102974_b0165","doi-asserted-by":"crossref","unstructured":"M. H. Damlaj, S. Call, T. Witzig, T. E. Nowakowski, G. S. Shanafelt, T. Ding, W. Oliveira, J. Ketterling, R. Litzow, M. R. Hogan, W. Patnaik, M., \u201cFeasibility of hematopoietic stem cell transplantation for T-prolymphocytic leukemia. Experience of a large referral center,\u201d (in English), Biology of Blood and Marrow Transplantation, Conference Abstract vol. 1), p. S185, February 2015. [Online]. Available: http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed16&AN=71798285.","DOI":"10.1016\/j.bbmt.2014.11.281"},{"key":"10.1016\/j.ctrv.2025.102974_b0170","doi-asserted-by":"crossref","unstructured":"M.-V. Mateos et al., \u201cRandomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA,\u201d in Journal of Clinical Oncology, 2019, vol. 36, no. 15_suppl: American Society of Clinical Oncology, pp. TPS8058-TPS8058, doi: 10.1200\/JCO.2018.36.15_suppl.TPS8058.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8058"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102974_b0175","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"The lancet haematology"},{"key":"10.1016\/j.ctrv.2025.102974_b0180","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00277-021-04405-2","article-title":"Subcutaneous daratumumab in asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study","volume":"100","author":"Iida","year":"2021","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102974_b0185","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5414\/CP202714","article-title":"\u201cEfficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis,\u201d (in english)","volume":"55","author":"Hu","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2025.102974_b0190","doi-asserted-by":"crossref","unstructured":"M. S. Merz, H. Haenel, M. Mai, E. K. Bertsch, U. Kunz, C. Hielscher, T. Blau, I. W. Scheid, C. Hose, D. Seckinger, A. Jauch, A. Hillengass, J. Raab, M. S. Schurich, B. Munder, M. Schmidt-Wolf, I. G. H. Gerecke, C. Lindemann, H. W. Zeis, M. Weisel, K. Duerig, J. Goldschmidt, H., \u201cSubcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: An interim analysis from the prospective GMMG-MM5 trial,\u201d (in English), Haematologica, vol. 100, no. 7, pp. 964-969, 06 Jul 2015, doi: 10.3324\/haematol.2015.124347.","DOI":"10.3324\/haematol.2015.124347"},{"key":"10.1016\/j.ctrv.2025.102974_b0195","first-page":"14","article-title":"\u201cSubcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy,\u201d (in english)","author":"Minarik","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.102974_b0200","doi-asserted-by":"crossref","unstructured":"S. D. A. Mu, L. S. Qin, Y. Hu, Y., \u201cSubcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis,\u201d (in English), Current medical science, vol. 38, no. 1, pp. 43-50, 01 Feb 2018, doi: 10.1007\/s11596-018-1844-y.","DOI":"10.1007\/s11596-018-1844-y"},{"key":"10.1016\/j.ctrv.2025.102974_b0205","unstructured":"S. L. Zhang, J. Liu, P., \u201cEfficacy and safety of subcutaneous bortezomib versus intravenous bortezomib in patients with multiple myeloma: A systematic review and meta-analysis,\u201d (in English), International Journal of Clinical and Experimental Medicine, Review vol. 11, no. 2, pp. 445-452, 2018. [Online]. Available: http:\/\/www.ijcem.com\/files\/ijcem0060599.pdf http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexa&AN=620792513."},{"key":"10.1016\/j.ctrv.2025.102974_b0210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8025","article-title":"\u201cSubcutaneous (SC) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone (Pd) in patients with relapsed\/refractory multiple myeloma (RRMM): interim phase 1b study results,\u201d ed","author":"Quach","year":"2022","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0215","doi-asserted-by":"crossref","unstructured":"S. L. D. Hill, A., \u201cSubcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia,\u201d (in English), Future Oncology, vol. 14, no. 17, pp. 1691-1699, July 2018, doi: 10.2217\/fon-2017-0574.","DOI":"10.2217\/fon-2017-0574"},{"key":"10.1016\/j.ctrv.2025.102974_b0220","doi-asserted-by":"crossref","unstructured":"A. M. Davies, F. Mihaljevic, B. Siritanaratkul, N. Solal-Celigny, P. Barrett, M. Berge, C. Bittner, B. Boehnke, A. McIntyre, C. MacDonald, D., \u201cPharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): Stage 1 analysis of a randomised phase 3 study,\u201d (in English), The Lancet Oncology, vol. 15, no. 3, pp. 343-352, March 2014, doi: 10.1016\/S1470-2045%2814%2970005-1.","DOI":"10.1016\/S1470-2045(14)70005-1"},{"key":"10.1016\/j.ctrv.2025.102974_b0225","doi-asserted-by":"crossref","unstructured":"A. B. Davies, C. Boehnke, A. Dadabhoy, A. Lugtenburg, P. Rule, S. Rummel, M. McIntyre, C. Smith, R. Badoux, X., \u201cSubcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development,\u201d (in English), Advances in Therapy, Review vol. 34, no. 10, pp. 2210-2231, 01 Oct 2017, doi: 10.1007\/s12325-017-0610-z.","DOI":"10.1007\/s12325-017-0610-z"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102974_b0230","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3747\/co.24.3470","article-title":"A canadian perspective on the subcutaneous administration of rituximab in non-hodgkin lymphoma","volume":"24","author":"Macdonald","year":"2017","journal-title":"(in English), Current Oncology, Review"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102974_b0235","first-page":"1556","article-title":"Subcutaneous administration of rituximab (MabThera) and trastuzumab (herceptin) using hyaluronidase","volume":"109","author":"Shpilberg","year":"2013","journal-title":"(in English), Br J Cancer, Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-US Gov't"},{"key":"10.1016\/j.ctrv.2025.102974_b0240","doi-asserted-by":"crossref","unstructured":"S. B. Assouline, V. Delmer, A. Gaidano, G. Trneny, M. Berthillon, N. Brewster, M. Catalani, O. Li, S. McIntyre, C. Sayyed, P. Badoux, X., \u201cPharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial,\u201d (in English), The Lancet Haematology, vol. 3, no. 3, pp. e128-e138, March 2016, doi: 10.1016\/S2352-3026%2816%2900004-1.","DOI":"10.1016\/S2352-3026(16)00004-1"},{"key":"10.1016\/j.ctrv.2025.102974_b0245","doi-asserted-by":"crossref","unstructured":"A. A. Salar, I. Bittner, B. Bouabdallah, R. Brewster, M. Catalani, O. Follows, G. Haynes, A. Hourcade-Potelleret, F. Janikova, A. Larouche, J. F. McIntyre, C. Pedersen, M. Pereira, J. Sayyed, P. Shpilberg, O. Tumyan, G., \u201cComparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: Results from a two-stage, phase IB study,\u201d (in English), Journal of Clinical Oncology, vol. 32, no. 17, pp. 1782-1791, 10 Jun 2014, doi: 10.1200\/JCO.2013.52.2631.","DOI":"10.1200\/JCO.2013.52.2631"},{"key":"10.1016\/j.ctrv.2025.102974_b0250","doi-asserted-by":"crossref","unstructured":"A. F. A. Rodrigues Ferreira, E., \u201cAdministration of Subcutaneous Monoclonal Antibodies in Patients With Cancer,\u201d (in English), Oncology nursing forum, vol. 46, no. 1, pp. E38-E47, 13 Jan 2019, doi: 10.1188\/19.ONF.E38-E47.","DOI":"10.1188\/19.ONF.E38-E47"},{"key":"10.1016\/j.ctrv.2025.102974_b0255","doi-asserted-by":"crossref","unstructured":"P. Solal-Celigny, \u201cRituximab by subcutaneous route,\u201d (in English), Expert Review of Hematology, Review vol. 8, no. 2, pp. 147-153, 01 Apr 2015, doi: 10.1586\/17474086.2015.1024651.","DOI":"10.1586\/17474086.2015.1024651"},{"key":"10.1016\/j.ctrv.2025.102974_b0260","doi-asserted-by":"crossref","unstructured":"A. A. Salar, I. Larouche, J. Janikova, A. Pereira, J. Brewster, M. Catalani, O. McIntyre, C. Sayyed, P. Haynes, A., \u201cFinal results of the BP22333 study demonstrate noninferior pharmacokinetics and safety of subcutaneous versus intravenous rituximab as maintenance therapy in follicular lymphoma,\u201d (in English), Hematological Oncology, Conference Abstract vol. 1), pp. 161-162, June 2013, doi: 10.1002\/hon.2058.","DOI":"10.1002\/hon.2058"},{"issue":"Suppl 3","key":"10.1016\/j.ctrv.2025.102974_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijn.12413","article-title":"Rituximab for subcutaneous delivery: clinical management principles from a nursing perspective","volume":"21","author":"Carlson","year":"2015","journal-title":"Int J Nurs Pract"},{"key":"10.1016\/j.ctrv.2025.102974_b0270","doi-asserted-by":"crossref","unstructured":"S. B. Assouline, V. Delmer, A. Gaidano, G. McIntyre, C. Brewster, M. Catalani, O. Hourcade-Potelleret, F. Sayyed, P. Badoux, X., \u201cPharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia,\u201d (in English), British Journal of Clinical Pharmacology, vol. 80, no. 5, pp. 1001-1009, 01 Nov 2015, doi: 10.1111\/bcp.12662.","DOI":"10.1111\/bcp.12662"},{"key":"10.1016\/j.ctrv.2025.102974_b0275","doi-asserted-by":"crossref","unstructured":"C. M. Jackisch, V. Dall, P. Neumeister, R. Park-Simon, T. W. Ruf-Dordelmann, A. Seiler, S. Tesch, H. Ataseven, B., \u201cSubcutaneous trastuzumab for HER2-positive breast cancer - Evidence and practical experience in 7 German centers,\u201d (in English), Geburtshilfe und Frauenheilkunde, vol. 75, no. 6, pp. 566-573, 10 Jun 2015, doi: 10.1055\/s-0035-1546172.","DOI":"10.1055\/s-0035-1546172"},{"issue":"9","key":"10.1016\/j.ctrv.2025.102974_b0280","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"\u201cSubcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial,\u201d (in english)","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0285","doi-asserted-by":"crossref","unstructured":"A. L. H. Quartino, C. Li, J. Li, H. Wada, R. D. Visich, J. Li, C. Heinzmann, D. Jin, J. Y. Lum, B. L., \u201cPopulation pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous \u201dmanual syringe\u201c injection or intravenously in women with HER2-positive early breast cancer,\u201d (in English), Cancer Chemother Pharmacol, Clinical Trial, Phase III Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't vol. 77, no. 1, pp. 77-88, Jan 2016, doi: doi: 10.1007\/s00280-015-2922-5.","DOI":"10.1007\/s00280-015-2922-5"},{"key":"10.1016\/j.ctrv.2025.102974_b0290","doi-asserted-by":"crossref","unstructured":"C. K. Jackisch, S. B. Semiglazov, V. Melichar, B. Pivot, X. Hillenbach, C. Stroyakovskiy, D. Lum, B. L. Elliott, R. Weber, H. A. Ismael, G., \u201cSubcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: Updated results from the phase III HannaH study,\u201d (in English), Annals of Oncology, vol. 26, no. 2, pp. 320-325, 01 Feb 2015, doi: 10.1093\/annonc\/mdu524.","DOI":"10.1093\/annonc\/mdu524"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102974_b0295","first-page":"85","article-title":"Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer","volume":"9","author":"Sanford","year":"2014","journal-title":"(in English), Target, Evaluation Studies Research Support, Non-US Gov't Review"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102974_b0300","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14737167.2019.1554437","article-title":"\u201cBehind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to central eastern european countries,\u201d (in eng)","volume":"19","author":"Inotai","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102974_b0305","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40265-013-0006-6","article-title":"\u201cSubcutaneous bortezomib: in multiple myeloma,\u201d (in english)","volume":"73","author":"Hoy","year":"2013","journal-title":"Drugs Review"},{"key":"10.1016\/j.ctrv.2025.102974_b0310","unstructured":"C. W. Fu, D. Zhu, X. Jin, S. Yan, L. Yan, S. Wang, P. Ge, Y. Chang, M., \u201cA pharmacokinetics clinical study of bortezomib subcutaneous injection versus intravenous injection combined with chemotherapy in chinese patients with newly diagnosed multiple myeloma-interim results,\u201d (in English), Haematologica, Conference Abstract vol. 101 (Supplement 1), p. 794, June 2016. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4894295\/pdf\/haematol_2016_s1.pdf http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed17&AN=615549046."},{"issue":"5","key":"10.1016\/j.ctrv.2025.102974_b0315","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cpt.2308","article-title":"Quantitative clinical pharmacology supports the bridging from iv dosing and approval of sc rituximab in B\u2010cell hematological malignancies","volume":"110","author":"Jamois","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102974_b0320","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3324\/haematol.2019.243790","article-title":"Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase ib study (PAVO)","volume":"106","author":"San-Miguel","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2025.102974_b0325","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2019-122765","article-title":"Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma: COLUMBA update","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102974_b0330","unstructured":"M. Kaiser et al., \u201cPhase 3, open-label, non-inferiority study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma: body weight subgroup analysis of Columba,\u201d in BRITISH JOURNAL OF HAEMATOLOGY, 2020, vol. 189: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, pp. 22-22."},{"key":"10.1016\/j.ctrv.2025.102974_b0335","unstructured":"M.-V. Mateos et al., \u201cEfficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA,\u201d ed: American Society of Clinical Oncology, 2019."},{"key":"10.1016\/j.ctrv.2025.102974_b0340","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2018.36.15_suppl.8013","article-title":"Subcutaneous daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO)","volume":"vol. 36, no. 15_suppl","author":"Chari","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0345","doi-asserted-by":"crossref","unstructured":"P. L. Clemens et al., \u201cPharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO),\u201d vol. 132, no. Suppl 1, pp. 2006-2006, 2018, doi: 10.1182\/blood-2018-99-113161 %J Blood.","DOI":"10.1182\/blood-2018-99-113161"},{"key":"10.1016\/j.ctrv.2025.102974_b0350","doi-asserted-by":"crossref","unstructured":"S. Lonardi et al., \u201cCheckMate 8KX: Phase 1\/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (\u00b1rHuPH20),\u201d ed: Wolters Kluwer Health, 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.2575"},{"key":"10.1016\/j.ctrv.2025.102974_b0355","doi-asserted-by":"crossref","unstructured":"C. Jackson et al., \u201c171P Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX: A multitumor study of a subcutaneous (SC) formulation of nivolumab (NIVO) monotherapy,\u201d Immuno-Oncology and Technology, vol. 16, 2022.","DOI":"10.1016\/j.iotech.2022.100283"},{"key":"10.1016\/j.ctrv.2025.102974_b0360","unstructured":"K. Sanghavi, H. Vezina, A. Roy, B. Murthy, A. Bello, and U. Aras, \u201cNivolumab pharmacokinetics when administered subcutaneously in patients with solid tumors: population pharmacokinetic analysis from checkmate 8kx,\u201d in Clinical pharmacology & therapeutics, 2022, vol. 111: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, pp. S45-S45."},{"key":"10.1016\/j.ctrv.2025.102974_b0365","doi-asserted-by":"crossref","unstructured":"X. S. Pivot, J. P. Espie, M. Cottu, P. Jouannaud, C. Pottier, V. Moreau, L. Extra, J. M. Lortholary, A. Rivera, P. Spaeth, D. Attar-Rabia, H. Benkanoun, C. Dima-Martinez, L. Esposito, N. Gligorov, J., \u201cPatients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study,\u201d (in English), European Journal of Cancer, Randomized Controlled Trial Research Support, Non-U.S. Gov't vol. 82, pp. 230-236, 09 2017, doi: doi: 10.1016\/j.ejca.2017.05.009.","DOI":"10.1016\/j.ejca.2017.05.009"},{"key":"10.1016\/j.ctrv.2025.102974_b0370","unstructured":"Spanish Breast Cancer Research Group. \u201cPhase III to Evaluate Patient\u0301s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (ChangHER-SC).\u201d https:\/\/clinicaltrials.gov\/study\/NCT01875367 (accessed 10\/10\/2023."},{"issue":"4","key":"10.1016\/j.ctrv.2025.102974_b0375","article-title":"Phase III study to evaluate patient\u2019s preference of subcutaneous versus intravenous trastuzumab in HER2\u2010positive metastatic breast cancer patients: results from the ChangHER study (GEICAM\/2012\u201007)","volume":"29","author":"Ciruelos","year":"2020","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.ctrv.2025.102974_b0380","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejca.2021.03.047","article-title":"Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study","volume":"152","author":"O'Shaughnessy","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.102974_b0385","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.annonc.2020.03.020","volume":"31","author":"O'Shaughnessy","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0390","unstructured":"CT.gov. \u201cA Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHranceSCa).\u201d https:\/\/clinicaltrials.gov\/study\/NCT03674112 (accessed 10\/10\/2023."},{"issue":"1","key":"10.1016\/j.ctrv.2025.102974_b0395","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102974_b0400","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00280-021-04296-0","article-title":"Population pharmacokinetic and exploratory exposure\u2013response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study","volume":"88","author":"Wang","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2025.102974_b0405","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.annonc.2021.03.060","volume":"32","author":"Im","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0410","doi-asserted-by":"crossref","first-page":"S1431","DOI":"10.1016\/j.annonc.2022.10.008","article-title":"1MO the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study","volume":"33","author":"Shao","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0415","unstructured":"X. G. Pivot, J. Muller, V. Barrett-Lee, P. Knoop, A. Curigliano, G. Jenkins, V. Scotto, N. Osborne, S. Fallowfield, L., \u201cPatients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the treatment of HER2-positive early breast cancer: Final analysis of 488 patients in the international, randomised, two-cohort PrefHer study,\u201d (in English), European Journal of Cancer, Conference Abstract vol. 2), pp. S109-S110, March 2014, doi: 10.1016\/S0959-8049%2814%2970090-5."},{"key":"10.1016\/j.ctrv.2025.102974_b0420","doi-asserted-by":"crossref","unstructured":"J. C. P. Byrd, B. L. Rai, K. R. Hurd, D. Hohl, R. Perry, M. C. Gockerman, J. Nattam, S. Larson, R. A., \u201cFludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901,\u201d (in English), Leuk Lymphoma, Clinical Trial, Phase II Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't vol. 50, no. 10, pp. 1589-96, Oct 2009. [Online]. Available: http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med6&AN=19863336.","DOI":"10.1080\/10428190903150839"},{"key":"10.1016\/j.ctrv.2025.102974_b0425","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2021-147136","article-title":"A multi-center, phase 1b study to assess the safety, pharmacokinetics and efficacy of subcutaneous isatuximab plus pomalidomide and dexamethasone, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Moreau","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102974_b0430","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10549-020-05604-7","article-title":"Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer","volume":"181","author":"Denys","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2025.102974_b0435","unstructured":"F. N. Bacchiarri, C. Antonioli, E. Staderini, M. Barone, F. Guarrera, A. Messeri, M. Coltro, G. Grieco, P. Bosi, A., \u201cSafetyand efficacy of subcutaneous versus intravenous bortezomib in patients with newly elderly diagnosed multiple myeloma,\u201d (in English), Haematologica, Conference Abstract vol. 102 (Supplement 3), p. 167, October 2017. [Online]. Available: http:\/\/www.haematologica.org\/content\/102\/s3\/1.full.pdf+html http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexa&AN=620886234."},{"key":"10.1016\/j.ctrv.2025.102974_b0440","doi-asserted-by":"crossref","unstructured":"J. C. Gligorov, G. Muller, V. Knoop, A. Jenkins, V. Verma, S. Osborne, S. Lauer, S. Machackova, Z. Fallowfield, L. Pivot, X., \u201cSwitching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial,\u201d (in English), Breast, vol. 34, pp. 89-95, August 2017, doi: 10.1016\/j.breast.2017.05.004.","DOI":"10.1016\/j.breast.2017.05.004"},{"key":"10.1016\/j.ctrv.2025.102974_b0445","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/01.HS9.0000847400.79465.e8","article-title":"P1133: SUB-cutaneous rituximab induction followed by short rituximab maintenance improves pfs in patients with low-tumor burden follicular lymphoma. final results of flirt phase III trial, a Lysa study","volume":"6","author":"Cartron","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102974_b0450","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.clml.2020.08.014","article-title":"Effectiveness and safety of subcutaneous rituximab for patients with gastric MALT lymphoma: a case\u2013control comparison with intravenous rituximab","volume":"21","author":"Rotkopf","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ctrv.2025.102974_b0455","doi-asserted-by":"crossref","unstructured":"E. Fargier et al., \u201cSMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma,\u201d (in English), Annals of Hematology, vol. 97, no. 1, pp. 123-131, 01 Jan 2018, doi: 10.1007\/s00277-017-3147-y.","DOI":"10.1007\/s00277-017-3147-y"},{"key":"10.1016\/j.ctrv.2025.102974_b0460","doi-asserted-by":"crossref","unstructured":"S. R. Irwin, C. Cosh, H. Bloodworth, C., \u201cPositive benefits of changing from intravenous Rituximab administration to subcutaneousadministration: A single centre experience,\u201d (in English), British Journal of Haematology, Conference Abstract vol. 176 (Supplement 1), pp. 68-69, March 2017, doi: 10.1111\/bjh.14613.","DOI":"10.1111\/bjh.14613"},{"key":"10.1016\/j.ctrv.2025.102974_b0465","unstructured":"E. D.-D. Paszkiewicz-Kozik, M. Robak, P. J. Wojciechowska-Lampka, E. Swierkowska-Czeneszew, M. Tajer, J. Romejko-Jarosinska, J. Domanska-Czyz, K. Szymanski, M. Morawska, M. Targonski, L. Osowiecki, M. Ostrowska, B. Dabrowska-Iwanicka, A. P. Walewski, J., \u201cSubcutaneous compared to intravenous administration of rituximab plus CHOP in patients with diffuse large b-cell lymphoma-A study by the polish lymphoma research group,\u201d (in English), Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH, Conference Abstract vol. 130, no. Supplement 1, 2017. [Online]. Available: http:\/\/www.bloodjournal.org\/content\/130\/Suppl_1\/5217 http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexa&AN=620333853."},{"issue":"4","key":"10.1016\/j.ctrv.2025.102974_b0470","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1200\/OP.22.00421","article-title":"Clinical administration Characteristics of subcutaneous and intravenous Administration of Daratumumab in patients with multiple myeloma at Mayo Clinic infusion centers","volume":"19","author":"Soefje","year":"2023","journal-title":"JCO Oncology Practice"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102974_b0475","first-page":"166","article-title":"\u201cImplications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study,\u201d (in english), breast, Comparative study randomized controlled","volume":"24","author":"Fallowfield","year":"2015","journal-title":"Trial"},{"key":"10.1016\/j.ctrv.2025.102974_b0480","doi-asserted-by":"crossref","unstructured":"K. M. Petrakova, B. Bortlicek, Z. Hejduk, K., \u201cPreference of trastuzumab administration route (intravenous or subcutaneous) in patients in the Czech Republic. Cross-sectional study on 429 patients,\u201d (in English), Cancer Research. Conference: 39th Annual CTRC AACR San Antonio Breast Cancer Symposium. United States, Conference Abstract vol. 77, no. 4 Supplement 1, 2017, doi: 10.1158\/1538-7445.SABCS16-P4-21-12.","DOI":"10.1158\/1538-7445.SABCS16-P4-21-12"},{"key":"10.1016\/j.ctrv.2025.102974_b0485","doi-asserted-by":"crossref","unstructured":"O. C. Castillo-Fernandez, A. Arauz, E. Bellido, D. Lim, M. Lopez, R. Montano, L., \u201cDo patients and nurses outside clinical trial prefer subcutaneous trastuzumab over conventional intravenous infusion? Instituto Oncologico Nacional experience,\u201d (in English), Cancer Research. Conference: 39th Annual CTRC AACR San Antonio Breast Cancer Symposium. United States, Conference Abstract vol. 77, no. 4 Supplement 1, 2017, doi: 10.1158\/1538-7445.SABCS16-P5-11-16.","DOI":"10.1158\/1538-7445.SABCS16-P5-11-16"},{"key":"10.1016\/j.ctrv.2025.102974_b0490","doi-asserted-by":"crossref","unstructured":"X. G. Pivot, J. Muller, V. Verma, S. Knoop, A. Curigliano, G. Camci, C. Jenkins, V. Scotto, N. Osborne, S. Fallowfield, L., \u201cPatient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study,\u201d (in English), Cancer Research. Conference: 36th Annual CTRC AACR San Antonio Breast Cancer Symposium. San Antonio, TX United States. Conference Publication:, Conference Abstract vol. 73, no. 24 SUPPL. 1, 2013, doi: 10.1158\/0008-5472.SABCS13-P4-12-11.","DOI":"10.1158\/0008-5472.SABCS13-P4-12-11"},{"key":"10.1016\/j.ctrv.2025.102974_b0495","first-page":"S385","article-title":"Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study","volume":"2","author":"Fallowfield","year":"2013","journal-title":"(in English), European Journal of Cancer, Conference Abstract"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102974_b0500","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1177\/10781552221103551","article-title":"Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma","volume":"29","author":"Mateos","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ctrv.2025.102974_b0505","unstructured":"F. Badibouidi, L. Can-Kose, L. Dupont, C. Truttet, and F. Ait-Kac, \u201cSubcutaneous Daratumumab Versus Intravenous Daratumumab For The Treatment Of Patients With Multiple Myeloma: A Time, Motion And Cst Assessment Study In A General Hospital,\u201d vol. European Journal of Oncology Pharmacy, no. 6:1, 2023."},{"issue":"4","key":"10.1016\/j.ctrv.2025.102974_b0510","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0515","unstructured":"V. S. Tomarchio, M. A. Tafuri, M. A. Becilli, M. Sarlo, C. Berti, P. Ferraro, S. Proietti, R. Tafuro, G. Bolettieri, A. Ioele, D. Tassielli, D. Scerbo, G. Annibali, O., \u201cManagement, economic and social impact of sub-cutaneous rituximab administration in lymphoproliferative malignancies,\u201d (in English), Haematologica, Conference Abstract vol. 102 (Supplement 2), p. 298, June 2017. [Online]. Available: http:\/\/www.haematologica.org\/content\/102\/s2\/1.full.pdf+html http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed18&AN=617380419."},{"key":"10.1016\/j.ctrv.2025.102974_b0520","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-136543","article-title":"NHL patients and nurses in the US prefer subcutaneous rituximab injection versus intravenous rituximab infusion: a real-world study","volume":"136","author":"Gandhi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.102974_b0525","doi-asserted-by":"crossref","unstructured":"E. Ciruelos et al., \u201cAbstract OT3-01-03: Phase III clinical trial to evaluate patient's preference for subcutaneous (SC) versus intravenous (IV) trastuzumab administration in patients with HER2 positive, advanced breast cancer (ABC) under IV trastuzumab treatment for at least 4 months and without disease progression. ChangHER-SC study (GEICAM\/2012-07),\u201d vol. 76, no. 4 Supplement, pp. OT3-01-03-OT3-01-03, 2016, doi: 10.1158\/1538-7445.SABCS15-OT3-01-03 %J Cancer Research.","DOI":"10.1158\/1538-7445.SABCS15-OT3-01-03"},{"key":"10.1016\/j.ctrv.2025.102974_b0530","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.breast.2022.10.002","article-title":"Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference-substudy of the randomised phase III GAIN-2 study","volume":"66","author":"Reinisch","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2025.102974_b0535","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.annonc.2020.03.026","article-title":"86P patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial","volume":"31","author":"Reinisch","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102974_b0540","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059288","article-title":"Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time\u2013motion study with mixed-methods research","volume":"13","author":"Lin","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.ctrv.2025.102974_b0545","doi-asserted-by":"crossref","unstructured":"J. B. Mihajlovic, P. van Breugel, E. Blommestein, H. M. Hoogendoorn, M. Hospes, W. Postma, M. J., \u201cMicrocosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion,\u201d (in English), Clinical Therapeutics, vol. 39, no. 6, pp. 1221-1232.e4, June 2017, doi: 10.1016\/j.clinthera.2017.05.342.","DOI":"10.1016\/j.clinthera.2017.05.342"},{"key":"10.1016\/j.ctrv.2025.102974_b0550","doi-asserted-by":"crossref","unstructured":"S. E. Walzer, S. Profico, A. Canciani, M. Farina, M. Ponzetti, C., \u201cResource and cost savings due to subcutaneous versus intravenous administration of oncology therapies: case studies with rituximab (mabthera) and trastuzumab (herceptin),\u201d (in English), Value in Health, Conference Abstract vol. 18 (7), p. A466, November 2015. [Online]. Available: http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed16&AN=72083562.","DOI":"10.1016\/j.jval.2015.09.1220"},{"key":"10.1016\/j.ctrv.2025.102974_b0555","doi-asserted-by":"crossref","unstructured":"S. C. Rule, G. P. Samanta, K., \u201cSubcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: A time and motion study in the United Kingdom,\u201d (in English), Journal of Medical Economics, vol. 17, no. 7, pp. 459-468, July 2014, doi: 10.3111\/13696998.2014.914033.","DOI":"10.3111\/13696998.2014.914033"},{"key":"10.1016\/j.ctrv.2025.102974_b0560","unstructured":"R. O. Dillon, Y. Bowers, M. Hamilton, J. Carlin, P. El-Agnaf, M., \u201cSuccessful switch from intravenous to subcutaneous rituximab at the ulster hospital, Belfast, Northern Ireland,\u201d (in English), Haematologica, Conference Abstract vol. 101 (Supplement 1), p. 756, June 2016. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4894295\/pdf\/haematol_2016_s1.pdf http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed17&AN=615548889."},{"key":"10.1016\/j.ctrv.2025.102974_b0565","doi-asserted-by":"crossref","unstructured":"G. Lopez-Vivanco et al., \u201cCost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain,\u201d (in English), Clinical and Translational Oncology, vol. 19, no. 12, pp. 1454-1461, 01 Dec 2017, doi: 10.1007\/s12094-017-1684-4.","DOI":"10.1007\/s12094-017-1684-4"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102974_b0570","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14737167.2020.1764353","article-title":"The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology","volume":"21","author":"Altini","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ctrv.2025.102974_b0575","first-page":"S28","article-title":"Saving Healthcare and societal costs by changing the route of Administration of Oncology Drugs","volume":"vol. 21 (Supplement 3)","author":"Franken","year":"2018","journal-title":"(in English), Value in Health, Conference Abstract"},{"issue":"Supplement 2","key":"10.1016\/j.ctrv.2025.102974_b0580","first-page":"600","article-title":"\u201cCost-minimization analysis of rituximab subcutaneous formulation versus intravenous administration of rituximab for the treatment of non-hodgkin's lymphoma in the republic of Macedonia,\u201d (in english)","volume":"102","author":"Nikolov","year":"2017","journal-title":"Haematologica Conference Abstract"},{"key":"10.1016\/j.ctrv.2025.102974_b0585","first-page":"S108","article-title":"Cost minimization study between intravenous rituximab (R-IV) vs subcutaneous rituximab (R-SC) in thai patients with diffused Large B-CELL lymphoma (DLBCL): a simulation of electronic health record (E-HR) and evidence synthesis","volume":"vol. 21 (Supplement 2)","author":"Chansung","year":"2018","journal-title":"(in English), Value in Health, Conference Abstract"},{"key":"10.1016\/j.ctrv.2025.102974_b0590","unstructured":"A. S. Di Rocco, G. Ansuinelli, M. Petrucci, L. La Rocca, U. Coggi, A. Arduini, E. Foa, R. Martelli, M., \u201cEfficacy, safety and cost analysis of subcutaneous vs intravenous rituximab in patients with diffuse large B-cell lymphoma treated with RCHOP,\u201d (in English), Haematologica, Conference Abstract vol. 102 (Supplement 3), pp. 110-111, October 2017. [Online]. Available: http:\/\/www.haematologica.org\/content\/102\/s3\/1.full.pdf+html http:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexa&AN=620886287."},{"key":"10.1016\/j.ctrv.2025.102974_b0595","doi-asserted-by":"crossref","unstructured":"S. N. Olofsson, H. Karlsson, E. Wilking, U. Ragnarson Tennvall, G., \u201cSocietal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting,\u201d (in English), Breast, vol. 29, pp. 140-146, 01 Oct 2016, doi: 10.1016\/j.breast.2016.07.008.","DOI":"10.1016\/j.breast.2016.07.008"},{"key":"10.1016\/j.ctrv.2025.102974_b0600","doi-asserted-by":"crossref","unstructured":"J. J. Olsen, K. F. Olesen, D. S. Knoop, A., \u201cCosts of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer,\u201d (in English), Journal of Comparative Effectiveness Research, vol. 7, no. 5, pp. 411-419, May 2018, doi: 10.2217\/cer-2017-0048.","DOI":"10.2217\/cer-2017-0048"},{"key":"10.1016\/j.ctrv.2025.102974_b0605","unstructured":"C. Blein et al., \u201cA multi-center evaluation of clinical pathways cost and time using real-life data in patients treated for their breast cancer by Trastuzumab intravenous and subcutaneous in day sessions,\u201d ed. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Europe. Barcelona, Spain., 2018."},{"key":"10.1016\/j.ctrv.2025.102974_b0610","first-page":"423","article-title":"\u201cMedical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study,\u201d (in eng)","volume":"7","author":"North","year":"2015","journal-title":"ClinicoEconomics and outcomes research : CEOR"},{"key":"10.1016\/j.ctrv.2025.102974_b0615","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejogrb.2017.12.006","article-title":"\u201cSubcutaneous trastuzumab (herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: a time, motion and cost assessment study in a lean operating day care oncology unit,\u201d (in eng)","volume":"221","author":"Tjalma","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.102974_b0620","first-page":"A176","article-title":"\u201cEconomic analysis of subcutaneous trastuzumab use versus intravenous trastuzumab,\u201d (in english)","volume":"23","author":"Camean-Castillo","year":"2016","journal-title":"Eur J Hosp Pharm Conference Abstract"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102974_b0625","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1016\/j.clbc.2019.01.011","article-title":"Cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland","volume":"19","author":"O'Brien","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102974_b0630","first-page":"16","article-title":"Cost-minimisation analysis of intravenous versus subcutaneous trastuzumab regimen for breast cancer management in Hong Kong","volume":"29","author":"Lee","year":"2023","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.ctrv.2025.102974_b0635","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S0959-8049(22)01542-8","article-title":"Impact of subcutaneous versus intravenous administration of pertuzumab and trastuzumab (PH) for the treatment of HER2-positive breast cancer in Montenegro","volume":"175","author":"Saric","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.102974_b0640","doi-asserted-by":"crossref","unstructured":"D. Kashiura, P. Souza, A. Sa, B. Santos, E. Nardi, and M. Alves, \u201cBudget impact model of subcutaneous rituximab compared with intravenous rituximab in the treatment of CD-20 positive non-Hodgkin lymphoma in the Brazilian private healthcare system,\u201d ed. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Europe. Barcelona, Spain., 2018.","DOI":"10.1016\/j.jval.2018.09.149"},{"key":"10.1016\/j.ctrv.2025.102974_b0645","doi-asserted-by":"crossref","unstructured":"C. b. M. Blein, C. Priou, V. Borg, M. C. mouret-Reynier, M. Lebozec, G. Tournamille, J. Jaffre, A. Perez staub N Alfonsi, R. Attar Rabia, H. Bahmad, N., \u201cA Multicentric Evaluation of Consumables and Transports Cost of Breast Cancer Patient's Treated by Trastuzumab According to the Administration Form (Iv Versus Sc),\u201d (in English), Value in Health, Conference Abstract vol. 21 (Supplement 3), p. S30, October 2018, doi: 10.1016\/j.jval.2018.09.177.","DOI":"10.1016\/j.jval.2018.09.177"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102974_b0650","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41669-022-00361-3","article-title":"\u201cA systematic review of time and resource use costs of subcutaneous versus intravenous Administration of Oncology Biologics in a hospital setting,\u201d (in eng)","volume":"7","author":"McCloskey","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.ctrv.2025.102974_b0655","series-title":"presented at the European Hematology Association","article-title":"Assessment of clinical use parameters associated with a switch from intravenous to subcutaneous daratumumab administration in patients with multiple myeloma at mayo clinic","author":"Soefje","year":"2021"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102974_b0660","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"De Cock","year":"2016","journal-title":"(in English), PloS one"},{"key":"10.1016\/j.ctrv.2025.102974_b0665","doi-asserted-by":"crossref","unstructured":"E. P. De Cock, X. Hauser, N. Verma, S. Kritikou, P. Millar, D. Knoop, A., \u201cA time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer,\u201d (in English), Cancer Medicine, vol. 5, no. 3, pp. 389-397, 01 Mar 2016, doi: 10.1002\/cam4.573.","DOI":"10.1002\/cam4.573"},{"key":"10.1016\/j.ctrv.2025.102974_b0670","article-title":"Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T","volume":"vol. 42, no. 4","author":"George","year":"2024","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0675","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1310546","article-title":"\u201cPatient experience of medication administration and development of a patient Experience and preference questionnaire (PEPQ) for patients with advanced or metastatic cancer,\u201d (in eng)","volume":"15","author":"Skalicky","year":"2024","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102974_b0680","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.annonc.2023.05.009","volume":"34","author":"Burotto","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102974_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102706","article-title":"244MO Primary results from IMscin002: a study to evaluate patient (pt)-and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC","volume":"9","author":"Cappuzzo","year":"2024","journal-title":"ESMO Open"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:50:34Z","timestamp":1755499834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":137,"alternative-id":["S0305737225000969"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102974","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102974"}}